SCHEMBL25816474

SCHEMBL25816474

Cn1cc(C2CC(O)ON2C(=O)OC(C)(C)C)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.39
RIPK1 Q13546 1/20 0.37
USP30 Q70CQ3 2/20 0.36
HRH3 Q9Y5N1 1/20 0.34
HCAR2 Q8TDS4 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
ELANE P08246 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
RET P07949 3/20 0.32
GSK3B P49841 2/20 0.32
DYRK1A Q13627 2/20 0.32
WNT1 P04628 1/20 0.32
PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25818222 0.85 GPR119 (0.37) GPR119RIPK1USP30HRH3HCAR2
SCHEMBL25816371 0.82 GPR119 (0.36) GPR119CHRM2CHRM1CHRM3ELANE
SCHEMBL25295391 0.79 GPR119 (0.41) GPR119RIPK1USP30HCAR2ELANE
SCHEMBL28873156 0.79 GPR119 (0.41) GPR119RIPK1USP30HCAR2ELANE
SCHEMBL31205643 0.79 DGAT1 (0.37) GPR119
SCHEMBL25296814 0.79 ALDH1A1 (0.36)
SCHEMBL30547542 0.79 ALDH1A1 (0.36)
SCHEMBL30339061 0.78 NTRK1 (0.39)
SCHEMBL30338629 0.78 USP30 (0.37) GPR119USP30CHRM2CHRM1CHRM3
SCHEMBL30339094 0.78 NTRK1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 GPR119 420/4885RIPK1 1/4885USP30 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.